K-Ras(G12C) inhibitor 9 Clinical Trials

Size	Price	Qty
5mg	USD 197
25mg	USD 497

Clinical Trials

Numerous clinical trials evaluate targeted therapies and clinical strategies for KRAS-mutant and wild-type malignancies, primarily encompassing non-small cell lung cancer, metastatic colorectal cancer, neuroendocrine tumors, and ovarian cancer across Early Phase 1 through Phase 3 protocols. Supported by cooperative networks, industry partners, and academic institutions, these studies span varied operational statuses, including active, recruiting, completed, suspended, and terminated trials.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT07431827	RECRUITING	Non-small Cell Lung Cancer	Merck Sharp & Dohme LLC	2026-03-18	PHASE3
NCT07554339	RECRUITING	Non-small Cell Lung Cancer	Merck Sharp & Dohme LLC	2026-06-18	PHASE3
NCT07209111	RECRUITING	Neoplasm Malignant	Merck Sharp & Dohme LLC	2025-12-04	PHASE2
NCT07541170	RECRUITING	Non-small Cell Lung Cancer	Hoffmann-La Roche	2026-09-01	PHASE3
NCT05789082	RECRUITING	Non-Small Cell Lung Cancer	Hoffmann-La Roche	2023-06-20	PHASE1; PHASE2
NCT06645236	RECRUITING	Metastatic Colorectal Cancer (mCRC)	QIAGEN Gaithersburg, Inc	2023-12-22
NCT07124884	NOT_YET_RECRUITING	Colorectal Carcinoma; KRAS G12C Mutation; Unresectable Colorectal Cancer	Federation Francophone de Cancerologie Digestive	2025-08-31	PHASE2
NCT07639242	SUSPENDED	Lung Cancer; Lung Cancer (NSCLC); Locally Advanced NSCLC; Metastatic NSCLC - Non-Small Cell Lung Cancer	UNC Lineberger Comprehensive Cancer Center	2026-10	PHASE2
NCT05067283	RECRUITING	Advanced Solid Tumors	Merck Sharp & Dohme LLC	2021-12-17	PHASE1
NCT07190248	RECRUITING	Non-small Cell Lung Cancer	Merck Sharp & Dohme LLC	2025-10-08	PHASE3
NCT07542704	NOT_YET_RECRUITING	Advanced Solid Tumors; Colorectal Cancer (CRC); Non-Small Cell Lung Cancer; Uterine Cancer; KRAS G12C Mutations; KRAS G12S Mutations	Kumquat Biosciences Inc.	2026-05	PHASE1
NCT07252739	RECRUITING	Malignant Neoplasm	Merck Sharp & Dohme LLC	2025-12-19	PHASE2
NCT06875310	RECRUITING	Carcinoma, Non-Small-Cell Lung	Mirati Therapeutics Inc.	2025-04-24	PHASE3
NCT07286149	RECRUITING	Lung Neoplasm Malignant	Merck Sharp & Dohme LLC	2026-04-30	PHASE1; PHASE2
NCT06720987	RECRUITING	KRAS G12C Mutation; KRAS G12S Mutation; Solid Tumor Malignancies; CRC (Colorectal Cancer)	Kumquat Biosciences Inc.	2025-02-04	PHASE1
NCT07615413	NOT_YET_RECRUITING	KRAS G12C Mutation Advanced Solid Tumor	Jiangsu Hansoh Pharmaceutical Co., Ltd.	2026-06-30	PHASE1
NCT07543172	NOT_YET_RECRUITING	Advanced Lung Non-Small Cell Carcinoma; Stage III Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8	Roswell Park Cancer Institute	2026-10-15	PHASE2
NCT06890598	RECRUITING	Carcinoma, Non-Small-Cell Lung	Eli Lilly and Company	2025-03-27	PHASE3
NCT06997497	RECRUITING	Colon Adenocarcinoma; Rectal Adenocarcinoma	Merck Sharp & Dohme LLC	2025-07-16	PHASE3
NCT06412198	RECRUITING	Metastatic Colorectal Cancer; KRAS G12C Mutations	M.D. Anderson Cancer Center	2024-08-28	PHASE1; PHASE2
NCT06345729	RECRUITING	Non-small Cell Lung Cancer	Merck Sharp & Dohme LLC	2024-05-24	PHASE3
NCT07164170	RECRUITING	Non-Small Cell Lung Cancer	Abbisko Therapeutics Co, Ltd	2025-09-22	PHASE2
NCT06128551	RECRUITING	Non-Small Cell Lung Cancer (NSCLC); Colorectal Cancer; Pancreatic Ductal Adenocarcinoma	Revolution Medicines, Inc.	2023-11-14	PHASE1; PHASE2
NCT07589569	RECRUITING	Pancreatic Cancer	Shandong Suncadia Medicine Co., Ltd.	2026-06-04	PHASE2
NCT07581912	RECRUITING	Colorectal Cancer; KRAS G12C Mutant Advanced Solid Tumors; Fulzerasib; Cetuximab N01	Zhejiang University	2026-04-30	PHASE2
NCT06793215	RECRUITING	Non-Small Cell Lung Cancer; KRAS G12C Lung Cancer	Hoffmann-La Roche	2025-10-24	PHASE3
NCT04613596	RECRUITING	Advanced Non-Small Cell Lung Cancer; Metastatic Non-Small Cell Lung Cancer	Mirati Therapeutics Inc.	2020-12-02	PHASE2; PHASE3
NCT07294261	NOT_YET_RECRUITING	Local Advanced or Metastatic NSCLC	Sun Yat-sen University	2025-12-23	PHASE2
NCT07174908	RECRUITING	Non-Small Cell Lung Cancer	InxMed (Shanghai) Co., Ltd.	2025-09-10	PHASE3
NCT07601048	NOT_YET_RECRUITING	KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer Patients Who Have Failed Standard Treatment	Shandong Suncadia Medicine Co., Ltd.	2026-06	PHASE3
NCT07670013	RECRUITING	NSCLC	Second Affiliated Hospital, Zhejiang University, School of Medicine	2026-04-01	PHASE2
NCT05398094	RECRUITING	Non-small Cell Lung Cancer Stage III; KRAS P.G12C	Fundación GECP	2022-03-21	PHASE2
NCT07472478	NOT_YET_RECRUITING	Lung Cancer (NSCLC); KRAS G12C Lung Cancer	Guangdong Provincial People's Hospital	2026-03-15	PHASE2
NCT04449874	ACTIVE_NOT_RECRUITING	Non-Small Cell Lung Cancer; Colorectal Cancer; Advanced Solid Tumors	Genentech, Inc.	2020-07-29	PHASE1
NCT06166836	ACTIVE_NOT_RECRUITING	Solid Tumor	InxMed (Shanghai) Co., Ltd.	2022-10-12	PHASE1; PHASE2
NCT07242274	NOT_YET_RECRUITING	NSCLC (Non-small Cell Lung Cancer)	Jemincare	2025-12-31	PHASE3
NCT06119581	RECRUITING	Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis	Eli Lilly and Company	2023-12-21	PHASE3
NCT06244771	RECRUITING	Advanced Solid Tumors With KRAS G12C Mutations; Solid Tumor, Adult; Unresectable Solid Tumor; Metastatic Solid Tumor; Non Small Cell Lung Cancer; Colorectal Cancer; KRAS G12C; Pancreatic Cancer	Frontier Medicines Corporation	2024-02-12	PHASE1; PHASE2
NCT06435455	NOT_YET_RECRUITING	Locally Advanced or Metastatic Solid Tumors Harboring KRAS G12C Mutation	Suzhou Genhouse Bio Co., Ltd.	2024-07-01	PHASE1; PHASE2
NCT07339839	NOT_YET_RECRUITING	NSCLC Stage IV; KRAS G12C	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	2026-03-01	PHASE1; PHASE2
NCT07198841	RECRUITING	Lung Cancer (Non-Small Cell)	Guangdong Association of Clinical Trials	2025-11-03	PHASE2
NCT05815173	RECRUITING	Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation	NYU Langone Health	2023-08-01	PHASE1
NCT05999357	WITHDRAWN	Non Small Cell Lung Cancer Metastatic; Brain Metastases, Adult; KRAS G12C	Maastricht University Medical Center	2024-04-15	PHASE2
NCT07012031	RECRUITING	Locally Advanced Lung Non-Small Cell Carcinoma; Metastatic Lung Non-Small Cell Carcinoma; Stage III Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8	National Cancer Institute (NCI)	2026-06-17	PHASE1; PHASE2
NCT06959589	ENROLLING_BY_INVITATION	Colorectal Cancer Metastatic; KRAS G12C Mutation	Second Affiliated Hospital, Zhejiang University, School of Medicine	2025-05-22	PHASE2
NCT06936644	NOT_YET_RECRUITING	KRAS G12C Lung Cancer	Shanghai Chest Hospital	2025-04-30	PHASE2
NCT04956640	ACTIVE_NOT_RECRUITING	Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Endometrial Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Biliary Tract Neoplasms	Eli Lilly and Company	2021-07-19	PHASE1; PHASE2
NCT05288205	RECRUITING	KRAS P.G12C; Non-small Cell Lung Cancer; Colorectal Cancer; Pancreatic Ductal Carcinoma	Allist Pharmaceuticals, Inc.	2022-04-14	PHASE1; PHASE2
NCT06248606	RECRUITING	Non Small Cell Lung Cancer; NSCLC; KRAS G12C	Ryan Gentzler, MD	2024-08-06	PHASE2
NCT04699188	ACTIVE_NOT_RECRUITING	KRAS G12C Mutant Solid Tumors; Carcinoma, Non-Small-Cell Lung; Carcinoma, Colorectal; Cancer of Lung; Cancer of the Lung; Lung Cancer; Neoplasms, Lung; Neoplasms, Pulmonary; Pulmonary Cancer; Pulmonary Neoplasms	Novartis Pharmaceuticals	2021-02-24	PHASE1; PHASE2
NCT04625647	ACTIVE_NOT_RECRUITING	Lung Adenocarcinoma; Lung Non-Small Cell Carcinoma; Recurrent Lung Non-Squamous Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8	SWOG Cancer Research Network	2021-04-16	PHASE2
NCT05485974	ACTIVE_NOT_RECRUITING	Lung Cancer; Non Small Cell Lung Cancer; Colorectal Cancer; Cancer of Pancreas; Colon Cancer; Solid Tumor; Cancer	HUYABIO International, LLC.	2022-08-01	PHASE1
NCT04973163	ACTIVE_NOT_RECRUITING	Solid Tumors, KRAS Mutation	Boehringer Ingelheim	2021-09-09	PHASE1
NCT06249282	RECRUITING	Advanced Lung Non-Small Cell Carcinoma; Metastatic Lung Non-Small Cell Carcinoma; Stage III Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8	City of Hope Medical Center	2024-04-24	PHASE1
NCT06594874	NOT_YET_RECRUITING	Non-Small Cell Lung Cancer; Advanced Solid Tumors	Jiangsu Hansoh Pharmaceutical Co., Ltd.	2024-10-31	PHASE1
NCT07396090	NOT_YET_RECRUITING	Advanced Solid Tumor	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	2026-01-20
NCT05853575	ACTIVE_NOT_RECRUITING	Advanced Cancer; Metastatic Cancer; Malignant Neoplasm of Lung	Mirati Therapeutics Inc.	2024-02-01	PHASE2
NCT06300177	RECRUITING	Non Small Cell Lung Cancer	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	2024-03-28	PHASE3
NCT05358249	ACTIVE_NOT_RECRUITING	KRAS G12C Mutant Solid Tumors; Carcinoma, Non-Small Cell Lung; Carcinoma, Non-Small-Cell Lung; Non-Small Cell Lung Cancer; Non-Small Cell Lung Carcinoma; Nonsmall Cell Lung Cancer; Colorectal Cancer; Colorectal Carcinoma; Colorectal Neoplasms; Colorectal Tumors; Neoplasms, Colorectal	Novartis Pharmaceuticals	2022-10-24	PHASE1; PHASE2
NCT05609578	ACTIVE_NOT_RECRUITING	Advanced NSCLC; Metastatic Lung Cancer	Mirati Therapeutics Inc.	2022-11-22	PHASE2
NCT06068153	WITHDRAWN	Metastatic Non Small Cell Lung Cancer; KRAS G12C	ETOP IBCSG Partners Foundation	2025-03	PHASE2
NCT05132075	ACTIVE_NOT_RECRUITING	Non-Small Cell Lung Cancer	Novartis Pharmaceuticals	2022-06-15	PHASE3
NCT06582771	RECRUITING	Non Small Lung Cancer	Memorial Sloan Kettering Cancer Center	2024-08-30	PHASE2
NCT03785249	ACTIVE_NOT_RECRUITING	Advanced Cancer; Metastatic Cancer; Malignant Neoplastic Disease	Mirati Therapeutics Inc.	2019-01-15	PHASE1; PHASE2
NCT05375994	COMPLETED	Non Small Cell Lung Cancer; KRAS Activating Mutation; Advanced Cancer; Metastatic Cancer; Malignant Neoplasm of Lung; Malignant Neoplastic Disease	Verastem, Inc.	2022-08-01	PHASE1; PHASE2
NCT06383871	RECRUITING	Advanced Malignant Tumour	Shandong Suncadia Medicine Co., Ltd.	2024-06-06	PHASE1
NCT05074810	ACTIVE_NOT_RECRUITING	Non Small Cell Lung Cancer; KRAS Activating Mutation	Verastem, Inc.	2022-04-12	PHASE1; PHASE2
NCT06497556	ACTIVE_NOT_RECRUITING	Non-Small Cell Lung Cancer; KRAS G12C Lung Cancer	Hoffmann-La Roche	2024-09-23	PHASE3
NCT06838338	ACTIVE_NOT_RECRUITING	Colorectal Cancer	Jian Li	2025-03-20	PHASE1
NCT06946927	RECRUITING	NSCLC (Advanced Non-small Cell Lung Cancer)	Jemincare	2025-06-06	PHASE1
NCT06333678	TERMINATED	Non-Small Cell Lung Cancer	Memorial Sloan Kettering Cancer Center	2024-03-20	PHASE2
NCT04793958	ACTIVE_NOT_RECRUITING	Advanced Colorectal Cancer; Metastatic Colorectal Cancer	Mirati Therapeutics Inc.	2021-06-24	PHASE3
NCT05451056	UNKNOWN	Non Small Cell Lung Cancer	Yonsei University	2022-08-01	PHASE2
NCT05634525	WITHDRAWN	Metastatic Pancreatic Cancer	M.D. Anderson Cancer Center	2023-05-03	PHASE1
NCT06235983	COMPLETED	Advanced Solid Tumors	Eli Lilly and Company	2024-02-29	PHASE1
NCT05472623	WITHDRAWN	Resectable Non-Small Cell Lung Cancer	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	2023-03-21	PHASE2
NCT06127940	UNKNOWN	Non-small Cell Lung Cancer Metastatic	Karolinska University Hospital	2023-10-15	PHASE1
NCT05504278	RECRUITING	Advanced Non-Small Cell Lung Cancer	Innovent Biologics (Suzhou) Co. Ltd.	2022-09-20	PHASE1
NCT04933695	TERMINATED	Non-small Cell Lung Cancer	Amgen	2022-01-28	PHASE2
NCT06237400	UNKNOWN	KRAS G12C Mutant Advanced Solid Tumors	Suzhou Zelgen Biopharmaceuticals Co.,Ltd	2022-05-26	PHASE1; PHASE2
NCT05194995	ACTIVE_NOT_RECRUITING	Advanced Colorectal Cancer; Small Intestinal Cancer; Appendiceal Cancer	Allist Pharmaceuticals, Inc.	2022-02-17	PHASE1; PHASE2
NCT05756153	COMPLETED	Advance Non-small Cell Lung Cancer	Genfleet Therapeutics (Shanghai) Inc.	2023-04-25	PHASE1; PHASE2
NCT05815186	WITHDRAWN	Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation	NYU Langone Health	2024-04	PHASE2
NCT05002270	COMPLETED	Advanced Solid Tumor; NSCLC; CRC	Jacobio Pharmaceuticals Co., Ltd.	2021-09-03	PHASE1; PHASE2
NCT05497336	TERMINATED	Colorectal Cancer	Innovent Biologics (Suzhou) Co. Ltd.	2022-08-18	PHASE1
NCT05840510	TERMINATED	Solid Tumor, Adult; NSCLC; Advanced Cancer; Metastatic Cancer; Malignant Neoplastic Disease	Mirati Therapeutics Inc.	2023-08-07	PHASE1
NCT05445843	ACTIVE_NOT_RECRUITING	Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation	Novartis Pharmaceuticals	2022-12-06	PHASE2
NCT06117371	COMPLETED	Advanced or Metastatic Solid Tumor; KRAS G12C Mutation	BeBetter Med Inc	2023-09-18	PHASE1
NCT05311709	UNKNOWN	Lung Cancer; NSCLC, Stage III; NSCLC Stage IV; Lung Cancer Stage IV; Mutation; Cancer; Cancer, Lung	Vestre Viken Hospital Trust	2022-05-30	PHASE2
NCT05480865	TERMINATED	Solid Tumor, Adult; Metastatic Solid Tumor; Metastatic NSCLC; Non Small Cell Lung Cancer	Navire Pharma Inc., a BridgeBio company	2022-07-06	PHASE1
NCT05054725	COMPLETED	Non-Small Cell Lung Cancer	Revolution Medicines, Inc.	2021-12-30	PHASE2
NCT06130254	TERMINATED	Advanced Solid Tumor; Non-small Cell Lung Cancers	M.D. Anderson Cancer Center	2024-01-30	PHASE1
NCT05492045	TERMINATED	NSCLC	InventisBio Co., Ltd	2022-09-13	PHASE1; PHASE2
NCT06024174	TERMINATED	Advanced Solid Tumors	Bristol-Myers Squibb	2023-11-09	PHASE1; PHASE2
NCT04585035	ACTIVE_NOT_RECRUITING	Solid Tumor, Adult; NSCLC; CRC	InventisBio Co., Ltd	2020-10-02	PHASE1; PHASE2
NCT05848843	WITHDRAWN	Lung Cancer; Gastro-intestinal Cancer	M.D. Anderson Cancer Center	2023-04-25	PHASE1
NCT05400577	WITHDRAWN	Non-Small Cell Lung Cancer	Fox Chase Cancer Center	2022-07-13	PHASE2
NCT04685135	ACTIVE_NOT_RECRUITING	Metastatic Non Small Cell Lung Cancer; Advanced Non Small Cell Lung Cancer	Mirati Therapeutics Inc.	2021-02-23	PHASE3
NCT05263986	UNKNOWN	Advanced or Metastatic Solid Tumor	Zai Lab (Shanghai) Co., Ltd.	2022-05-30	PHASE1
NCT05993455	UNKNOWN	Efficacy	Korea University Anam Hospital	2023-07-03	PHASE2
NCT05374538	TERMINATED	Non-small Cell Lung Cancer	Vitrac Therapeutics, LLC	2022-11-09	PHASE1
NCT05313009	TERMINATED	Non-Small Cell Lung Cancer	Medical University of South Carolina	2022-03-07	PHASE1; PHASE2
NCT04967079	COMPLETED	Non Small Cell Lung Cancer	Shanghai Chest Hospital	2021-08-01	PHASE1
NCT05178888	COMPLETED	Advanced Solid Tumor	Mirati Therapeutics Inc.	2022-01-20	PHASE1
NCT05119933	UNKNOWN	Advanced Solid Tumor	Shanghai YingLi Pharmaceutical Co. Ltd.	2021-11-09	PHASE1; PHASE2
NCT05347745	COMPLETED	Colo-rectal Cancer	QIAGEN Gaithersburg, Inc	2022-01-07
NCT05010694	UNKNOWN	Advanced Solid Tumors Harboring With G12C Mutation	Suzhou Genhouse Bio Co., Ltd.	2021-09-27	PHASE1
NCT05005234	COMPLETED	KRAS G12C	Innovent Biologics (Suzhou) Co. Ltd.	2021-09-13	PHASE1; PHASE2
NCT05251038	WITHDRAWN	Pancreatic Cancer; Unresectable Pancreatic Cancer; Metastatic Pancreatic Cancer; KRAS P.G12C	Devalingam Mahalingam	2022-09-13	PHASE1; PHASE2
NCT05180422	WITHDRAWN	Non Small Cell Lung Cancer	Criterium, Inc.	2022-06-15	PHASE1; PHASE2
NCT04975256	TERMINATED	Advanced Cancer; Metastatic Cancer; Malignant Neoplasm of Colon; Malignant Neoplasm of Lung; Malignant Neoplastic Disease	Mirati Therapeutics Inc.	2021-07-28	PHASE1
NCT04330664	COMPLETED	Advanced Cancer; Metastatic Cancer; Malignant Neoplastic Disease	Mirati Therapeutics Inc.	2020-04-07	PHASE1
NCT04236102	COMPLETED	Pancreatic Adenocarcinoma; Lung Cancer	Royal Cornwall Hospitals Trust	2020-07-07
NCT02395016	COMPLETED	Pancreatic Cancer	Biotech Pharmaceutical Co., Ltd.	2015-04	PHASE3
NCT01079780	COMPLETED	Colorectal Cancer	Eastern Cooperative Oncology Group	2011-01-18	PHASE2
NCT04165031	TERMINATED	Advanced Solid Tumor; Non-Small Cell Lung Cancer; Colorectal Cancer	Eli Lilly and Company	2019-11-28	PHASE1; PHASE2
NCT04006301	COMPLETED	Neoplasms; Advanced Solid Tumors; Non-small Cell Lung Cancer; Colorectal Cancer	Janssen Research & Development, LLC	2019-07-26	PHASE1
NCT01802645	UNKNOWN	Colorectal Cancer	Technische Universität Dresden	2013-03	PHASE2
NCT04342676	COMPLETED	Colon Cancer Stage III	Mansoura University	2017-03-10	PHASE3
NCT01051167	COMPLETED	Metastatic Colorectal Cancer	Martin Schuler, Prof. Dr. med.	2009-02	PHASE2
NCT01251536	COMPLETED	Colorectal Cancer	Universitaire Ziekenhuizen KU Leuven	2010-12	PHASE2
NCT01646554	WITHDRAWN	Colorectal Cancer Metastatic; Liver Metastases; KRAS Mutated Colorectal Cancer	European Organisation for Research and Treatment of Cancer - EORTC	2012-12	PHASE2; PHASE3
NCT01540344	TERMINATED	Peritoneal Carcinomatosis; Colorectal Cancer Metastatic	University of Regensburg	2010-10	PHASE2
NCT01410214	UNKNOWN	Non-small Cell Lung Cancer Stage IIIA	Chinese Lung Cancer Surgical Group	2011-05	PHASE2
NCT01338558	WITHDRAWN	Colorectal Cancer	Hoffmann-La Roche	2011-06	PHASE3
NCT01008475	COMPLETED	Metastatic Colorectal Cancer	Merck KGaA, Darmstadt, Germany	2009-10	PHASE1; PHASE2
NCT01288339	COMPLETED	Metastatic Colorectal Cancer	Grupo Espanol Multidisciplinario del Cancer Digestivo	2010-11-08	PHASE2
NCT01042288	COMPLETED	Non-Small-Cell Lung Cancer	SCRI Development Innovations, LLC	2010-06	PHASE2
NCT01450319	COMPLETED	Colorectal Neoplasms	Merck KGaA, Darmstadt, Germany	2011-12	PHASE2
NCT01215539	COMPLETED	Colorectal Cancer	Hellenic Cooperative Oncology Group	2010-09	PHASE2
NCT01126112	COMPLETED	Colorectal Cancer	Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)	2010-05	PHASE2
NCT00941499	COMPLETED	Advanced Cancers	M.D. Anderson Cancer Center	2009-07	PHASE1
NCT00655161	COMPLETED	NSCLC	GlobeImmune	2008-04	PHASE2
NCT05278728	COMPLETED	Colorectal Cancer	Biotech Pharmaceutical Co., Ltd.	2009-07	PHASE1; PHASE2
NCT00803647	COMPLETED	Metastatic Colorectal Cancer	NSABP Foundation Inc	2010-01	PHASE2
NCT00869570	COMPLETED	Colorectal Cancer	Swiss Cancer Institute	2009-03	PHASE1; PHASE2
NCT01277406	COMPLETED	Advanced Colorectal Carcinoma	4SC AG	2011-01	PHASE1; PHASE2
NCT01060423	TERMINATED	Colorectal Cancer	Hans-Joachim Schmoll, MD	2010-02	PHASE2
NCT00594984	COMPLETED	Metastatic Colorectal Cancer (MCRC)	Bristol-Myers Squibb	2008-05	PHASE1; PHASE2
NCT01281761	COMPLETED	Metastatic Colorectal Cancer	Samsung Medical Center	2010-11	PHASE2
NCT01149434	TERMINATED	Cancer; Neuroendocrine; Ovarian Cancer; Colon Cancer	University of Utah	2010-09	PHASE1; PHASE2
NCT01190462	UNKNOWN	Colorectal Cancer	Leiden University Medical Center	2010-08	PHASE2
NCT00964457	UNKNOWN	Rectum Cancer	Copenhagen University Hospital at Herlev	2009-08	PHASE2
NCT01116271	COMPLETED	Colorectal Cancer	AstraZeneca	2010-04	PHASE2
NCT01085331	TERMINATED	Metastatic Colorectal Cancer	EMD Serono	2010-03	PHASE1; PHASE2
NCT01110785	UNKNOWN	Colorectal Cancer	Leiden University Medical Center	2010-04	PHASE2
NCT00640471	COMPLETED	Colorectal Cancer	NCIC Clinical Trials Group	2008-05-12	PHASE3
NCT01086267	COMPLETED	Colorectal Cancer	Bristol-Myers Squibb	2010-07	PHASE1; PHASE2
NCT00660582	COMPLETED	Metastatic Colorectal Cancer	Per Pfeiffer	2008-04	PHASE2
NCT01380795	TERMINATED	Non-small Cell Lung Cancer Metastatic	Centre Georges Francois Leclerc	2011-03-09	EARLY_PHASE1
NCT00845039	TERMINATED	Colon Cancer; Rectal Cancer	Eli Lilly and Company	2009-05	PHASE2
NCT00989469	COMPLETED	Metastatic Colorectal Cancer	Institut du Cancer de Montpellier - Val d'Aurelle	2009-02	PHASE1; PHASE2
NCT01032291	TERMINATED	Colorectal Cancer	Celgene Corporation	2009-12	PHASE2
NCT01126450	TERMINATED	Colon Cancer; Rectal Cancer	Case Comprehensive Cancer Center	2009-10	PHASE1
NCT00640081	COMPLETED	Colorectal Cancer	Cheryl Pugh	2007-07	PHASE2
NCT00814619	COMPLETED	Colorectal Cancer	Swiss Cancer Institute	2008-11	PHASE2
NCT00972465	UNKNOWN	Advanced Colorectal Cancer	Peking University	2009-06	PHASE2
NCT00005630	COMPLETED	Lung Cancer	Memorial Sloan Kettering Cancer Center	1999-07	PHASE1

(data from https://clinicaltrials.gov, updated on 2026-08-28)

Check the K-Ras(G12C) inhibitor 9 product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

K-Ras(G12C) inhibitor 9 selectively binds allosterically to the mutant K-Ras(G12C) protein, locking it in an inactive conformation and suppressing downstream RAF-MEK-ERK signaling cascade activation. This biochemical blockade inhibits oncogenic signal transduction and halts tumor cell proliferation, demonstrating clinical relevance in targeting KRAS-driven malignancies such as non-small cell lung cancer and colorectal cancer.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).